Nonetheless, a number of studies have demonstrated recurrent ICC mutations including neomorphic alterations in IDH1 and IDH2, loss-of-function mutations in PBRM1, BAP1, TP53, ARID1A, and gain-of-function mutations in KRAS. This evidence concerns the gene TP53 and intrahepatic cholangiocarcinoma.